Gilead Sciences, Inc. $GILD Holdings Boosted by First Trust Advisors LP

First Trust Advisors LP raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 2.5% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,065,019 shares of the biopharmaceutical company’s stock after acquiring an additional 73,386 shares during the period. First Trust Advisors LP owned approximately 0.25% of Gilead Sciences worth $456,841,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new stake in shares of Gilead Sciences during the second quarter worth $15,393,785,000. State Street Corp grew its position in Gilead Sciences by 2.3% in the 2nd quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company’s stock valued at $7,734,099,000 after buying an additional 1,357,967 shares during the last quarter. Amundi grew its position in Gilead Sciences by 10.7% in the 1st quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock valued at $1,468,836,000 after buying an additional 1,018,976 shares during the last quarter. Legal & General Group Plc acquired a new position in Gilead Sciences in the 2nd quarter valued at $1,316,606,000. Finally, Deutsche Bank AG acquired a new position in Gilead Sciences in the 2nd quarter valued at $918,387,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

GILD has been the subject of a number of analyst reports. Royal Bank Of Canada upped their price objective on shares of Gilead Sciences from $126.00 to $131.00 and gave the stock a “sector perform” rating in a research report on Friday, October 30th. Needham & Company LLC set a $175.00 target price on shares of Gilead Sciences in a report on Friday, October 30th. TD Cowen set a $175.00 target price on shares of Gilead Sciences in a report on Wednesday. Sanford C. Bernstein reiterated an “outperform” rating and set a $175.00 price target on shares of Gilead Sciences in a research note on Monday, November 2nd. Finally, Bank of America increased their price target on shares of Gilead Sciences from $168.00 to $172.00 and gave the stock a “buy” rating in a report on Tuesday, October 20th. Twenty-three equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $171.63.

Get Our Latest Analysis on Gilead Sciences

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $170.55, for a total transaction of $4,775,400.00. Following the transaction, the insider directly owned 110,684 shares in the company, valued at approximately $18,877,156.20. This represents a 20.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Keeley Cain Wettan sold 3,399 shares of the stock in a transaction dated Friday, November 6th. The shares were sold at an average price of $164.11, for a total transaction of $557,809.89. Following the completion of the transaction, the executive vice president directly owned 5,360 shares of the company’s stock, valued at approximately $879,629.60. This trade represents a 38.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 237,709 shares of company stock worth $39,799,137 in the last ninety days. Corporate insiders own 0.30% of the company’s stock.

Gilead Sciences Trading Down 0.1%

NASDAQ:GILD opened at $166.33 on Friday. The stock has a fifty day moving average price of $157.26 and a two-hundred day moving average price of $142.46. The stock has a market capitalization of $206.30 billion, a price-to-earnings ratio of -52.64 and a beta of 0.35. The company has a debt-to-equity ratio of 1.84, a quick ratio of 1.22 and a current ratio of 1.38. Gilead Sciences, Inc. has a 1 year low of $116.88 and a 1 year high of $176.58.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last released its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, beating analysts’ consensus estimates of $2.19 by $0.36. The company had revenue of $8.30 billion during the quarter, compared to the consensus estimate of $7.81 billion. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. Gilead Sciences’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same quarter last year, the company earned $2.47 earnings per share. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post -0.97 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be issued a dividend of $0.82 per share. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.0%. Gilead Sciences’s payout ratio is currently -103.80%.

Gilead Sciences Profile

(Free Report)

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.

See Also

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.